Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01Sep 1, 2026
Biologics
Commercial Thinking Begins in Clinical Phases
Mathias Kahl
IDT Biologika
PAO-08-26-CL-02Sep 1, 2026
TPDs
Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs
David O’Connell
PCI Pharma Services
PAO-08-26-CL-04Aug 31, 2026
Lipase Risk
An Integrated Analytical Approach to Lipase Risk Management in Biologics Development
Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun
Samsung Biologics
PAO-08-26-CL-10Aug 31, 2026
New Brand
QPharma Builds on a Trusted Legacy to Shape the Future of Complex Drug Delivery
QPharma
PR-08-26-04Aug 31, 2026
Fun
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Samsung Biologics
PR-08-26-03Aug 31, 2026
Partner Selection
How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?
Pharma's Almanac
PAO-08-26-RT-01Aug 28, 2026
Chinese Biopharma
Pharmaceutical Innovation in China Takes Center Stage
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-17Aug 25, 2026
Potency Assurance
Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-16Aug 24, 2026
Supply Chain
Supply Chain Resilience in 2026: Any Progress?
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-15Aug 19, 2026
New Facilities
SK pharmteco Marks Construction Progress with Ribbon Cutting for Two Advanced Manufacturing Facilities at Swords, Ireland Campus
SK pharmteco
PR-08-26-02Aug 18, 2026
AOCs
Antibody–Oligonucleotide Conjugates Clinical Manufacturing — A New Paradigm Shift of Bio-Conjugates for Therapeutics
Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.
GBI Biomanufacturing
PAO-08-26-CL-08Aug 11, 2026
Supply Chain
Supply Chain Resilience Is Not an Insurance Cost, but Value Protection
Anurag Bhagania
OneSource Specialty Pharma
PAO-08-26-CL-07Aug 6, 2026
Self-Injection
The Quiet Revolution in How We Take Our Medicine
Ravi Kumar
OneSource Specialty Pharma
PAO-08-26-CL-06Aug 6, 2026
Innovation Partner
CDMOs as Innovation Partners in R&D
Prateek Gupta, Ph.D.
OneSource Specialty Pharma
PAO-08-26-CL-05Aug 6, 2026
Cell Therapy
NueCell Bio Launches as a New Translational Partner to Accelerate Cell Therapies from Discovery into GMP Manufacturing
NueCell Bio
PR-08-26-01Aug 5, 2026
Asia Manufacturing
The New Manufacturing Map of Asia
Pharma's Almanac
PAO-08-26-PA-03Aug 5, 2026
Asia Manufacturing
APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities
Pharma's Almanac
PAO-08-26-PA-02Aug 3, 2026
Geopolitics
How are geopolitical factors influencing sourcing and manufacturing decisions for 2026 and beyond?
Pharma's Almanac
PAO-07-26-RT-01Jul 30, 2026
ADC Formulation
Controlling Complexity in ADC Formulation Development
Eunbi Iris Cho, Ph.D.
Samsung Biologics
PAO-07-26-CL-04Jul 28, 2026